The Value of Sacubitril and Valsartan in Adjuvant Treatment of Coronary Heart Disease and Heart Failure

  • Wenbo Li Shaanxi Provincial People’s Hospital
  • Hang Meng Shaanxi Provincial People’s Hospital
DOI: https://doi.org/10.18686/aem.v11i3.275
Keywords: Coronary Heart Disease, Heart Failure, Sacubitril-Valsartan, Benazepril, Cardiac Function, 6min Walking Distance, Adverse Reactions, Efficacy

Abstract

Objective: To analyze the intervention effect of adjuvant sacubitril-valsartan therapy in patients with coronary heart disease and heart failure. Methods: A total of 89 patients with coronary heart disease and heart failure who were treated in our hospital in the past 3 years (January 2019-February 2022) were selected, and the clinical data were reviewed. 45 patients treated with conventional treatment + sacubitril and valsartan were used as the observation group, and the application values of the two groups were compared. Results: The improvement of various cardiac function levels in the observation group was better, the 6min walking distance was longer, and the adverse reaction rate was lower, and the difference was statistically significant compared with the control group (P<0.05). Conclusion: Sacubitril-valsartan has good effect in adjuvant treatment of coronary heart disease and heart failure, can effectively improve its cardiac function, improve exercise endurance, and has few adverse reactions, high safety, and definite clinical application value.

References

[1] Zhang MY, Liu H. The Clinical Value of Sacubitril and Valsartan in the Treatment of Coronary Heart Disease and Chronic Heart Failure[J]. China Health Nutrition, 2021.31(32): 51.

[2] Deng YH, Qin WJ, Yan SL, et al. Clinical Observation of Sacubitril and Valsartan in the Treatment of Elderly Patients with Chronic Heart Failure Caused by Coronary Heart Disease [J]. Chinese Journal of Hospital Pharmacy, 2021, 41(22):2338-2341.

[3] Liu AM, Shen Q. Analysis of the Efficacy of Sacubitril and Valsartan Sodium in the Treatment of Patients with Coronary Heart Disease and Heart Failure and Its Impact on Cardiac Function [J]. China Practical Medicine, 2020, 15(29): 139-141.

[4] Wu YT, Wang YH, Yao L, et al. Effects of Sacubitril and Valsartan on Cardiac Function in Elderly Patients with Coronary Heart Disease and Chronic Heart Failure [J]. Chinese Journal of Evidence-Based Cardiovascular Medicine, 2022, 14(5 ): 559-561+564.

[5] Zhang Y. Clinical Efficacy of Sacubitril and Valsartan in the Treatment of Elderly Heart Failure[J]. Tianjin Pharmacy, 2021, 33(1):26-27.
Published
2022-11-02
Issue
Vol 11 No 3 (2022)
Section
Original Research Article

Copyright (c) 2022 Wenbo Li, Hang Meng

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear

Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.